Trial Profile
Immunogenicity and Safety Study of GSK Biologicals' Trivalent Split Virion Influenza Vaccine Fluviral (2009 - 2010 Season) in Adults Aged 18 to 60 Years and Over 60 Years.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs GSK 1536489A (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 15 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Aug 2009 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 10 Jul 2009 New trial record